In general practices across Victoria and New South Wales, a group of nurses tried a patient-centred way of pushing back against the slow, largely invisible build-up of dementia risk in middle age. Their HAPPI MIND trial, now published, offers a measured answer: a nurse-guided program with a companion app nudged estimated risk scores in the right direction, but it did not yet change how people think, feel about their lives, or measure on their hearts. It is a small, honest step in a long effort to act on a disease whose roots are planted decades before its symptoms appear.
Nurse-Led App Program Modestly Improves Dementia Risk Scores, But Cognition Shows No Gain
Risk scores moved a little; memory and thinking did not
Mark
So what actually improved here?
Mimi
A questionnaire score estimating future dementia risk. 56% of the intervention group improved versus 44% of controls, a 1.6-point adjusted difference.
Mark
That sounds small. Is it?
Luke
It's modest, and the authors say so. It's also a score of estimated risk, not a count of dementia cases. Nothing here shows fewer people will develop dementia.
Mark
And cognition?
Mimi
No significant difference, and none in quality of life or cardiovascular risk either.
Luke
Worth adding that the main result shrank after further baseline adjustment. The groups weren't well matched to begin with.
Mark
Why does the nurse role matter?
Mimi
Practice nurses already do chronic disease counseling in Australia, and the trial tested whether that existing relationship could carry prevention work.
Mark
Did people use the app?
Mimi
80% attended at least four sessions, but only 35% used the app for 13 weeks or more.
Luke
So we can't say the app did anything. The report states the independent effect of the mHealth component is unclear.
Mark
Any hints about who benefits most?
Luke
Low socioeconomic status and high baseline risk, but those were exploratory, the first group was small, and the estimate was uncertain. Treat them as questions, not findings.
Le Pouls
- A cluster trial across 31 Australian practices tested whether nurse-led coaching and a smartphone app could curb dementia risk in people aged 45 to 65.
- Fifty-six percent of intervention participants improved their risk scores, against forty-four percent of controls, a modest 1.6-point gap that narrowed under further adjustment.
- Retention slipped to 78 percent in the intervention arm, and only 35 percent of those given the app used it for thirteen weeks or more.
- Cognition, quality of life, and cardiovascular measures showed no significant gains, and two deaths and a distressing adverse event raised questions the trial cannot fully settle.
- Researchers now look to a 36-month follow-up to learn whether score improvements endure and whether they ever translate into fewer dementia cases.
In general practices across Victoria and New South Wales, a group of nurses tried a patient-centred way of pushing back against the slow, largely invisible build-up of dementia risk in middle age. Their HAPPI MIND trial, now published, offers a measured answer: a nurse-guided program with a companion app nudged estimated risk scores in the right direction, but it did not yet change how people think, feel about their lives, or measure on their hearts. It is a small, honest step in a long effort to act on a disease whose roots are planted decades before its symptoms appear.
In thirty-one general practices across Victoria and New South Wales, practice nurses sat down with patients in their forties, fifties, and early sixties and asked them to change the habits that quietly raise the odds of dementia later on. Each participant had at least two modifiable risk factors and a smartphone or tablet, and the nurses offered six sessions over two years, personalized risk reports, practical goals, and a companion app to keep the work going between visits.
The results, published in The Lancet Regional Health – Western Pacific, are modest. After twelve months, 56 percent of the intervention group had improved their scores on the ANU-ADRI, a questionnaire-based dementia risk index, compared with 44 percent of those who received only a brief baseline intervention and usual care. The adjusted gap was 1.6 points, and it shrank when the analysts accounted for baseline differences that already tilted toward the intervention arm.
Beyond that single measure, little moved. Cognition, quality of life, cardiovascular risk, and clinical markers showed no meaningful separation between the groups. Both arms saw cholesterol and blood pressure improve, and the intervention group reported greater satisfaction with social life, though diet and medication adherence scores slipped there too. Engagement was uneven: most participants attended the sessions, but few used the app consistently. Two serious events linked to the intervention involved distress tied to existing disordered eating, a reminder that asking people to examine their habits carries its own weight.
The authors are careful about what this means. Participants knew their assignment, outcomes were self-reported, and the app's own contribution remains unclear. Exploratory hints of larger benefits for people with lower socioeconomic status or high baseline risk need confirmation. The next checkpoint is a follow-up at 36 months, which will show whether the score gains last and whether they ever become fewer dementia cases.
In 31 general practices across Victoria and New South Wales, practice nurses sat down with middle-aged patients and tried something specific: change the habits that raise the odds of dementia later in life, with a smartphone app to keep the work going between visits. The results of that effort, the HAPPI MIND trial, have now been published in The Lancet Regional Health – Western Pacific. They are modest, and they come with real caveats.
The trial enrolled adults aged 45 to 65 who had visited their clinic in the previous 12 months, had at least two modifiable dementia risk factors, and had access to a smartphone or tablet. Practices were randomized, not individuals: 13 clinics to the intervention and 18 to control. Of 430 people who consented, 403 completed baseline assessment, 201 in the intervention group and 202 in the control group. Clinics recruited a median of 13 participants each. People with neurological disease, terminal illness, or an inability to consent or communicate in English were excluded.
The intervention consisted of six nurse-led sessions, five in the first year and one at 24 months. Nurses produced personalized risk reports, set practical and measurable goals with each participant, used motivational interviewing, reviewed progress, and referred people to a general practitioner when further assessment was warranted. Participants used the HAPPI MIND app to monitor themselves, track goals, and read educational material. Controls received a brief baseline intervention, including screening with the ANU-ADRI, a risk report, and an educational booklet, then carried on with usual care.
The ANU-ADRI, a questionnaire-based index of future dementia risk where lower scores are better, was the primary measure. At 12 months, 56% of the intervention group had improved scores versus 44% of controls, an adjusted difference of 1.6 points. Further analyses pointed the same way, though the estimated effect shrank after additional adjustment for baseline differences. Retention differed too: 78% in the intervention arm and 88% in the control arm.
Beyond that score, the picture is flat. No significant differences appeared in cognition, quality of life, cardiovascular risk, psychosocial measures, or clinical and biomarker results. Both groups saw LDL cholesterol improve, total cholesterol fall among those who started high, and diastolic blood pressure drop among those with elevated baseline readings. Within the intervention group, satisfaction with social and leisure activities rose and harmful alcohol use fell, but MIND diet and medication adherence scores slipped. Controls also saw worse diet and adherence scores and higher absolute cardiovascular risk. Intervention participants did improve more on ANU-ADRI components covering physical activity, fish intake, and BMI status, though those comparisons were not adjusted for multiple testing.
Engagement was uneven. Eighty percent of the intervention group attended at least four sessions, but only 35% used the app for 13 weeks or more. Seven participants had adverse events, including two deaths, one in each group, and five serious events. Two of those were judged intervention-related and involved distress tied to pre-existing disordered eating.
The authors list several limits. Participants and providers knew their allocation, outcomes were self-reported, recruitment happened after clinics were randomized, the groups differed at baseline (physical inactivity, uncontrolled diabetes, BMI, and socioeconomic status, with risk scores numerically higher in the intervention arm), and follow-up differed. Whether the app itself contributed anything remains unclear. Exploratory analyses hinted at larger benefits for people with low socioeconomic status or high baseline risk, and for those whose nurses addressed social isolation, but the low-socioeconomic subgroup was small and the estimate uncertain.
The trial did not show better cognition or a reduction in dementia cases. Follow-up is planned to 36 months, which should reveal whether the score gains last, and larger implementation studies will have to address sustainability, generalisability, and cost-effectiveness.
Citations marquantes
The trial did not show improved cognition or establish a reduction in dementia incidence.— HAPPI MIND study conclusion, as reported by News-Medical
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Technology